Aktis Oncology Inc · Q1 2026 earnings

Briefing

Aktis Oncology reported Q1 2026 collaboration revenue of $3.2M, a net loss of $18.3M, and diluted loss per share of $0.38.

For the three months ended March 31, 2026, Aktis recognized collaboration revenue of $3.2 million, up from $1.4 million. R&D expense was $20.0 million; net loss was $18.3 million ($0.38 diluted loss per share) versus $15.0 million and $0.31 loss. Interest income of $4.4 million helped fund radiopharmaceutical platform development.

• Collaboration revenue $3.2M (+123% YoY).
• R&D $20.0M on radiopharmaceutical pipeline advancement.
• Net loss $18.3M; diluted EPS loss $0.38.
• Interest income $4.4M on strong cash/investment balance.
• Pre-commercial biotech; no product sales.

Headline financials

Revenue & EPS history

Clinical-stage company; 10-Q focuses on trial milestones and collaboration funding without revenue guidance.